Organotypic Tissue Culture for Substance Evaluation

Berlin, (PresseBox) - 22. September 2009 bis 25. September 2009

The Symposium aims to bring together latest state of the art of in vitro organ culture. It challenges the problem of multi-organ in vitro systems and finally tries to estimate, how far in vitro organs are from being valid systems for industrial high content substance testing.

Dynamic macroscale bioreactor systems are the most recent breakthrough in cell culture technology. With more than seven commercially avail- able liver bioreactor systems for acute liver failure, tissue engineers were able to fully emulate functions of a complex human organ in vitro for the first time in the hundred years of cell culture technology. This has resulted in spectacular long term performance over several weeks at a patient's bedside. This major achievement at the beginning of the 21st century fortunately coincided with an embarrassing gap in the measures to predict safety and the mode of action of chemicals, cosmetics, air particles or pharmaceuticals. This was fully recognized through eye-opening disasters and substance recalls worldwide. Neither animal tests nor conventional human cell line or tissue testing have been able to reflect the complex interaction of the substances with consumers biology at organ level. Tremendous efforts initiated in response to this situation have already led to a few impressive human in vitro systems, reduced in size and able to provide research data on individual aspects of substance interaction with human organisms.

Mehr Informationen gibt es auf http://events.dechema.de/tissue09.html

Cluster Gesundheitswirtschaft Berlin-Brandenburg - HealthCapital

BioTOP ist Anlaufstelle für alle Belange der Biotechnologie in Berlin-Brandenburg. BioTOP ist eine Initiative der Länder Berlin und Brandenburg in der TSB Innovationsagentur Berlin GmbH.

Press releases you might also be interested in

Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.


I want to subscribe to the gratis press mail and have read and accepted the conditions.